Coordination Pharmaceuticals

About Coordination Pharmaceuticals

Coordination Pharmaceuticals, Inc. operates in the immuno-oncology sector, focusing on the commercialization of its proprietary nanoscale coordination polymer (NCP) technology. This platform is designed to enhance the efficacy of cancer immunotherapy by increasing T cell infiltration into solid tumors, particularly those that are lowly immunogenic. The NCP technology allows for the co-delivery of disparate cancer therapeutics, such as chemotherapy and photodynamic therapy, to achieve synergistic antitumor effects while minimizing toxicity. The company primarily targets recurrent and metastatic solid tumors, offering a potent combination with checkpoint blockade inhibitors. Coordination Pharmaceuticals generates revenue through the development and commercialization of its NCP-based products, serving clients in the healthcare and pharmaceutical industries. The business model is centered around leveraging its advanced technology platform to provide effective treatment solutions for challenging cancer types.